Viewing Study NCT00495144



Ignite Creation Date: 2024-05-05 @ 6:32 PM
Last Modification Date: 2024-10-26 @ 9:34 AM
Study NCT ID: NCT00495144
Status: COMPLETED
Last Update Posted: 2012-07-27
First Post: 2007-06-28

Brief Title: A Phase I Study of the Safety Pharmacokinetics and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
Sponsor: Threshold Pharmaceuticals
Organization: Threshold Pharmaceuticals

Study Overview

Official Title: A Phase I Multi-Center Open-Label Dose-Escalation Study of the Safety Pharmacokinetics and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
Status: COMPLETED
Status Verified Date: 2012-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This is a phase I multi-center open-label dose-escalation study of TH-302 in patients with advanced solid tumors TH-302 is a hypoxia activated product designed to exploit the hypoxic nature of tumors The study is designed to establish the safety including the maximum tolerated dose the pharmacokinetics and the anti-tumor activity of TH-302
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None